Development code · Biologic
LY2062430
LY2062430 is a development code for Solanezumab, developed by Eli Lilly and Company.
- Status
- Discontinued for Alzheimer's disease
- Mechanism
- Amyloid-beta (aggregated) Inhibitor
- Developer
- Eli Lilly and Company
Programs
- Solanezumab for Alzheimer's diseaseDiscontinuedDiscontinued
Also known as
- LY-2062430
- solanezumab
- 955085-14-0
- m266 (humanized)